Head and Neck Cancers Coverage from Every Angle

Recent News

FDA Grants Orphan Drug Designation for AL101 in Adenoid Cystic Carcinoma
Alternative Chemotherapy Regimen to Cisplatin in Locally Advanced Head/Neck Cancer
Potential Applications of Machine Learning and Radiomics in Head and Neck Cancers
NIH Releases Latest PDQ Cancer Information Summary on Head and Neck Cancers
Phase II Study of Lenvatinib in Recurrent or Metastatic Adenoid Cystic Carcinoma
Mount Sinai Begins Clinical Trials in Head and Neck Cancers
Head and Neck Cancer’s Genetic Relationship to Other Cancers
Use of New Nomogram in Predicting Lymph Node Metastasis in Papillary Thyroid Cancer
AACR 2019: Can the Timing of Radiotherapy Affect the Severity of Oral Mucositis?
Novel Approach to Predicting Adverse and Beneficial Effects of Immunologic Interventions
Why Are Young Nonsmokers Presenting With Glottic Carcinomas?
Use of Minimally Invasive Biopsy for Early-Stage Oral Cancer
2019 ASCO-SITC: Tumor Growth Rate and Outcomes With Nivolumab in Head and Neck Cancer
2019 ASCO-SITC Symposium: Regulatory T Cells and Treatment Resistance in Head/Neck Cancer
2019 ESMO TAT: Predicting Outcomes With Lung Immune Prognostic Index
Is Incidence of Thyroid Cancer in United States Related to Malpractice Climate?
FDA Grants Priority Review to Pembrolizumab in First-Line Therapy for Metastatic Head/Neck Cancer
Gene Mutations by Smoking Status in Head and Neck Cancer
Using Genetic Biomarker to Predict Outcome in HPV-Related Oropharyngeal Cancer
KEYNOTE-040 Supports Benefit of Pembrolizumab in Resistant Head and Neck Cancer
Oropharyngeal Cancer and Opioid Use
Phase II Durvalumab Trial in Resistant Head and Neck Cancer
Is HPV on the Rise in Oropharyngeal Cancers?
Radiotherapy Plus Chemotherapy in HPV-Positive Oropharyngeal Cancer
Early Study of Lestaurtinib in Anaplastic Thyroid Cancer
Five-MicroRNA Signature: Predicting Outcomes in HPV-Negative Head and Neck Cancer
Human Papillomavirus and Pathways to Oncogenesis
Post Hoc Analysis of Pembrolizumab Versus Standard of Care in Head and Neck Cancer
FDA Approves Larotrectinib in Solid Tumors With NTRK Gene Fusion
Intensity-Modulated Radiotherapy for Head and Neck Squamous Cell Carcinomas

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.